Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.70 |
| ▸ | MELK | Q14680 | 2/20 | 0.53 |
| ▸ | ATM | Q13315 | 13/20 | 0.52 |
| ▸ | ATR | Q13535 | 6/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.52 |
| ▸ | MTOR | P42345 | 2/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 12/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22963991 | 0.90 | LRRK2 (0.62) | LRRK2MELKATMATRPIK3CA | |
| SCHEMBL31013172 | 0.90 | LRRK2 (0.62) | LRRK2MELKATMATRPIK3CA | |
| Hydrochloric Acid SCHEMBL27242947 | 0.89 | LRRK2 (0.61) | LRRK2MELKATMATRPIK3CA | |
| SCHEMBL27242853 | 0.88 | LRRK2 (0.56) | LRRK2MELKATMATRPIK3CA | |
| SCHEMBL31013184 | 0.85 | LRRK2 (0.57) | LRRK2MELK | |
| SCHEMBL27242945 | 0.85 | LRRK2 (0.57) | LRRK2MELK | |
| SCHEMBL29725496 | 0.84 | LRRK2 (0.53) | LRRK2ATMATRPIK3CAMTOR | |
| SCHEMBL22964213 | 0.83 | LRRK2 (0.55) | LRRK2MELK | |
| SCHEMBL29725417 | 0.83 | LRRK2 (0.55) | LRRK2MELK | |
| SCHEMBL22964216 | 0.83 | LRRK2 (0.55) | LRRK2MELKATMPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | claimed |
| CN-114174279-B | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | claimed |
| EP-4010317-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-06-19 | — | — | EP | claimed |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-08 | — | — | US | claimed |
| EP-4010317-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | claimed |
| CN-114174279-A | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-03-11 | — | — | CN | claimed |
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| CN-114174279-B | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-4010317-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-09-08 | — | — | US | disclosed |
| EP-4010317-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-06-15 | — | — | EP | disclosed |
| CN-114174279-A | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | 百时美施贵宝公司 | 2022-03-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12492186-B2 | Bicyclic heterocyclic compounds useful as IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | LRRK2 1015/4885MELK 1357/4885ATM 701/4885 |
| US-20220281844-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | LRRK2 1015/4885MELK 1357/4885ATM 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.